Field adherence to highly active antiretroviral therapy in HIV-infected adults in Abidjan, Côte d'Ivoire

Journal of Acquired Immune Deficiency Syndromes

Volumn 45, Issue 3, 2007, Pages 355-358

  Eholié, Serge Paul ^a   Tanon, Aristophane ^a   Polneau, Sandrine ^b   Ouiminga, Mariama ^a   Djadji, Ayoman ^a   Kangah Koffi, Constance ^a   Diakité, Nafissatou ^c   Anglaret, Xavier ^d   Kakou, Aka ^a   Bissagnené, Emmanuel ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE TREICHVILLE   (Côte d’Ivoire)

^b UNIVERSITÉ FÉLIX HOUPHOUËT BOIGNY   (Côte d’Ivoire)

^c Centre antituberculeux d'Adjamé Adjamé   (Côte d’Ivoire)

^d INSERM   (France)

Author keywords

Adherence; Adults; AIDS; C te d'Ivoire; Highly active antiretroviral therapy; Sub Saharan Africa

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ADVERSE OUTCOME; ARTICLE; CONTROLLED STUDY; DRUG COST; FEAR; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVENTION STUDY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTPATIENT DEPARTMENT; PATIENT COMPLIANCE; PHARMACY; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RISK; SELF REPORT; STATISTICAL ANALYSIS; URBAN POPULATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COTE D'IVOIRE; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; QUESTIONNAIRES; RISK FACTORS; SOCIOECONOMIC FACTORS; URBAN POPULATION;

EID: 34347338692     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31805d8ad0     Document Type: Article

References (20)

1. Kartenstein D, Laga M, Moatti JP. The evaluation of the HIV/AIDS Drug Access Initiatives in Côte d'Ivoire, Senegal and Uganda: how access to antiretroviral treatment can become feasible in Africa. AIDS. 2003;17:S1-S4.
2. Laurent C, Diakhaté N, Ngom Gueye NF, et al. The Senegalese government's HAART initiative: an 18-month follow up study of feasibility, effectiveness, adherence, toxicity and viral resistance. AIDS. 2002;16:1363-1370.
3. Orrel C, Bangsberg DR, Badri M, et al. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS. 2003;17:1369-1375.
4. Tassie JM, Szumilin E, Calmy A, et al. Médecins Sans Frontières. Highly active antiretroviral therapy in resource-poor settings: the experience of Médecins Sans Frontières. AIDS. 2003;17:1995-1997.
5. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load and development of drug resistance in an indigent population. AIDS. 2000;14:357-366.
6. Farmer CK. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21:1074-1090.
7. Landman R, Schieman R, Thiam S, et al. Once-a-day highly active antiretroviral therapy in treatment naïve HIV-1 infected adults in Senegal. AIDS. 2003;17:1017-1022.
8. Lanièce I, Ciss M, Desclaux A, et al. Adherence to HAART and it principal determinants in a cohort of Senegalese adults. AIDS. 2003;17:S103-S108.
9. Nemes MIB, Carvalho HB, Souza MFM. Antiretroviral adherence in Brazil. AIDS. 2004;18:S15-S20.
10. Gill CJ, Hamer DH, Simon JL, et al. No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. AIDS. 2005;19:1243-1249.
11. Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3:e438.
12. Weidle PJ, Malamba S, Mwebaze R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patient's response, survival and drug resistance. Lancet. 2002;360:34-40.
13. Hosseinipour MC, Kazembe PN, Sanne IM, et al. Challenges in delivering antiretroviral treatment in resource poor countries. AIDS. 2002;16:177-187.
14. Carrieri MP, Raffi F, Lewden C, et al. APROCO study group. Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study. Antivir Ther. 2003;8:585-594.
15. Gordillo V, Delamo J, Soriano V, et al. Socio-demographic and psychological variables influencing adherence to antiretroviral therapy. AIDS. 1999;13:1763-1769.
16. Diomandé FVK, Bissagnéné E, Nkengasong JN, et al. The most efficient use of resources to identify those in need of antiretroviral treatment in Africa: empirical data from Côte d'Ivoire. AIDS. 2003;17:S87-S93.
17. Kent DM, McGrath D, Ionnadis JPA, et al. Suitable monitoring approaches to antiretroviral therapy in resource-poor settings: setting the research agenda. Clin Infect Dis. 2003;37:S13-S24.
18. World Health Organization. Antiretroviral drugs for the treatment of HIV-infection in adults and adolescents in resource-limited settings; recommendations for a public health approach (2005-2006 revisions). Guidelines Development Group, brief meeting report; Montreux, Switzerland, June 22-23, 2005. Available at: http://www.who.int/3by5/ARVmeetingreport_june2005.pdf. Accessed September 1, 2005.
19. Koenig SP, Léandre F, Farmer PE. Scaling-up HIV treatment programmes in resource-limited settings: the rural Haiti experience. AIDS. 2004;18:21-25.
20. Eholié SP, Nolan M, Gaumon AP, et al. Antiretroviral treatment can be cost-saving for industry and life saving for workers: a case study from Côte d'Ivoire's private sector. In: Economics of AIDS and Access to HIV/AIDS Care in Developing Countries. Issues and Challenges. Paris, France: Collections Sciences Sociales et SIDA, ANRS; 2003: 329-346.